Femasys

Femasys Quick Ratio

The Quick Ratio (Acid Test) of Femasys (FEMY) as of Oct 21, 2026 is 2.78. In the previous year, Quick Ratio (Acid Test) was 0.49 — a change of 472.22% (higher).

Quick Ratio

2.78

YoY

472.22%

Last updated:

Quick Ratio (Acid Test) of Femasys is 2025 2.78 . Quick Ratio (Acid Test) of Femasys was 2024 0.49 . It decreases by 472.22% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Femasys Stock analysis

What does Femasys do? Femasys, Inc. generates revenue through the development and commercialization of its two lead product candidates, FemBloc and FemaSeed, alongside its FemEMB technology platform. FemBloc, a permanent birth control solution featuring dual intrauterine directional delivery with a degradable biopolymer, targets women seeking non-surgical contraceptive options. FemaSeed, an artificial insemination infertility treatment with single intrauterine directional delivery, addresses fertility challenges for patients. The FemEMB platform, designed for tissue sampling in physician offices, complements these products by enhancing diagnostic capabilities for women's health. These solutions are marketed to healthcare providers and clinics globally, focusing on improving patient care and health economics through office-based, non-surgical interventions. The company's revenue streams are derived from the sale of FemBloc, FemaSeed, and FemEMB to medical institutions and healthcare professionals. FemBloc targets women requiring permanent contraception, while FemaSeed serves patients with infertility issues. FemEMB supports physicians in conducting tissue sampling during routine office visits. The firm’s focus on non-surgical, office-based solutions positions it to serve a growing segment of women seeking accessible reproductive healthcare without invasive procedures. This approach aligns with the company’s mission to improve health economics by reducing the need for hospital-based interventions. Femasys, Inc. leverages its product portfolio to address key reproductive health needs through innovative, non-surgical technologies. FemBloc and FemaSeed are positioned as advanced alternatives to traditional methods, offering targeted delivery systems for contraception and fertility treatment. The FemEMB platform further enhances the company’s offerings by integrating diagnostic tools into standard office care. These products are sold to healthcare providers who serve women worldwide, emphasizing accessibility and improved patient outcomes. The company’s strategy centers on delivering solutions that meet the evolving demands of women’s healthcare in a cost-effective manner. Femasys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Femasys stock

Quick Ratio (Acid Test) of Femasys is 2.78 in 2025.

Quick Ratio (Acid Test) of Femasys changed from 0.49 to 2.78, representing a 472.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Femasys since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Femasys with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Femasys

All Key Metrics — Femasys